Peter Dreger

24.5k total citations · 1 hit paper
408 papers, 11.6k citations indexed

About

Peter Dreger is a scholar working on Hematology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Peter Dreger has authored 408 papers receiving a total of 11.6k indexed citations (citations by other indexed papers that have themselves been cited), including 195 papers in Hematology, 165 papers in Oncology and 155 papers in Pathology and Forensic Medicine. Recurrent topics in Peter Dreger's work include Lymphoma Diagnosis and Treatment (149 papers), Chronic Lymphocytic Leukemia Research (126 papers) and Hematopoietic Stem Cell Transplantation (122 papers). Peter Dreger is often cited by papers focused on Lymphoma Diagnosis and Treatment (149 papers), Chronic Lymphocytic Leukemia Research (126 papers) and Hematopoietic Stem Cell Transplantation (122 papers). Peter Dreger collaborates with scholars based in Germany, France and United Kingdom. Peter Dreger's co-authors include Norbert Schmitz, Torsten Haferlach, Thomas Luft, Meinolf Suttorp, Carsten Müller‐Tidow, Michael Schmitt, Anthony D. Ho, Anna Sureda, H. Löffler and Maria‐Luisa Schubert and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Peter Dreger

389 papers receiving 11.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

2020 340 citations Maria‐Luisa Schubert, Michael Schmitt et al. profile →

Peers

Countries citing papers authored by Peter Dreger

Since Specialization

Citations

This map shows the geographic impact of Peter Dreger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Dreger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Dreger more than expected).

Fields of papers citing papers by Peter Dreger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Dreger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Dreger. The network helps show where Peter Dreger may publish in the future.

Co-authorship network of co-authors of Peter Dreger

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Dreger. A scholar is included among the top collaborators of Peter Dreger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Dreger. Peter Dreger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study 2024 ·Blood Advances ·Simon Renders, (unknown), Hervé Finel, (unknown), William Townsend, Roland Schroers, Urban Novak, Nicolaas Schaap, Mahmoud Aljurf, Grzegorz Helbig, Matthew Collin, (unknown), (unknown), Josè Antonio Pérez-Simón, Adrian Bloor, Hervé Ghesquières, Anna Sureda, Norbert Schmitz, Bertram Glaß, Peter Dreger	0
2	Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation 2024 ·Best Practice & Research Clinical Haematology ·Thuong Hien Tran, Andreas Heinold, (unknown), (unknown), Matthias Stelljes, Peter Dreger	1
3	Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients – A clinical trial to registry data comparison 2024 ·Bone Marrow Transplantation ·Dietrich W. Beelen, Simona Iacobelli, Linda Köster, (unknown), Anja van Biezen, Friedrich Stölzel, Fabio Ciceri, Wolfgang Bethge, Peter Dreger, Eva Wagner-Drouet, Péter Reményi, Matthias Stelljes, Mirosław Markiewicz, Donal P. McLornan, Ibrahim Yakoub‐Agha, Mohamad Mohty	3
4	How risky is a second allogeneic stem cell transplantation? 2024 ·Leukemia ·Olaf Penack, (unknown), Christophe Peczynski, (unknown), Nicolaus Kröger, Robert Zeiser, Fabio Ciceri, Thomas Schroeder, Peter Dreger, Jakob Passweg, Johannes Schetelig, Matthias Stelljes, Igor Wolfgang Blau, Georg‐Nikolaus Franke, Katarina Riesner, Hélène Schoemans, Ivan Moiseev, Zinaida Perić	4
5	PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation 2024 ·Blood Cancer Journal ·Olaf Penack, (unknown), Christophe Peczynski, (unknown), Zafer Gülbaş, Tobias Gedde‐Dahl, Cristina Castilla‐Llorente, Nicolaus Kröger, M Eder, Alessandro Rambaldi, Francesca Bonifazi, Igor Wolfgang Blau, Matthias Stelljes, Peter Dreger, Ivan Moiseev, Hélène Schoemans, Christian Koenecke, Zinaida Perić	13
6	Allogeneic hematopoietic cell transplantation for older patients with AML with active disease. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT) 2024 ·Bone Marrow Transplantation ·Enrico Maffini, Myriam Labopin, Nicolaus Kröger, Jürgen Finke, Matthias Stelljes, Thomas Schroeder, Hermann Einsele, Johanna Tischer, Martin Bornhäuser, Wolfgang Bethge, Arne Brecht, Wolf Rösler, Peter Dreger, Kerstin Schäfer‐Eckart, Jakob Passweg, Igor Wolfgang Blau, Arnon Nagler, Fabio Ciceri, Mohamad Mohty	6
7	Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation 2023 ·Transplantation and Cellular Therapy ·Lukas John, Sandra Sauer, Ute Hegenbart, Peter Dreger, Michael Hundemer, Carsten Müller‐Tidow, Anita Schmitt, Michael Schmitt, Marc S. Raab, Stefan Schönland	4
8	Comparing the value of mono- vs coculture for high-throughput compound screening in hematological malignancies 2023 ·Blood Advances ·Sophie A. Herbst, Vladislav Kim, Tobias Roider, (unknown), Peter‐Martin Bruch, Nora Liebers, Carolin Kolb, (unknown), Junyan Lu, Peter Dreger, Carsten Müller‐Tidow, Thorsten Zenz, Wolfgang Huber, Sascha Dietrich	7
9	Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL 2022 ·Molecular Systems Biology ·Peter‐Martin Bruch, (unknown), Carolin Kolb, Sophie A. Herbst, (unknown), Tobias Roider, Junyan Lu, (unknown), Lena Wagner, (unknown), Ivan Berest, Mark Kriegsmann, Katharina Kriegsmann, Christiane Zgorzelski, Peter Dreger, Judith B. Zaugg, Carsten Müller‐Tidow, Thorsten Zenz, Wolfgang Huber, Sascha Dietrich	10
10	Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR 2020 ·Cancers ·Maria‐Luisa Schubert, Alexander Kunz, Anita Schmitt, Brigitte Neuber, Lei Wang, Angela Hückelhoven‐Krauss, Sascha Langner, Birgit Michels, Antje Wick, Volker Daniel, Carsten Müller‐Tidow, Peter Dreger, Michael Schmitt	14
11	Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients 2020 ·International Journal of Cancer ·(unknown), Keun-Young Yoo, Sophia Stock, Lei Wang, Yibin Liu, Maria‐Luisa Schubert, Sanmei Wang, Brigitte Neuber, Angela Hückelhoven‐Krauss, Ulrike Gern, Anita Schmitt, Carsten Müller‐Tidow, Peter Dreger, Michael Schmitt, Leopold Sellner	52
12	Interleukin-18 and Hematopoietic Recovery after Allogeneic Stem Cell Transplantation 2020 ·Cancers ·Aleksandar Radujkovic, Lambros Kordelas, (unknown), Carsten Müller‐Tidow, Dietrich W. Beelen, Peter Dreger, Thomas Luft	7
13	Interleukin-18 and outcome after allogeneic stem cell transplantation: A retrospective cohort study 2019 ·EBioMedicine ·Aleksandar Radujkovic, Lambros Kordelas, Hao Dai, David Schult, (unknown), Dietrich W. Beelen, Carsten Müller‐Tidow, Peter Dreger, Thomas Luft	13
14	Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy 2018 ·EBioMedicine ·Georg Gdynia, Tadeusz Robak, Jürgen Kopitz, Anette Heller, (unknown), (unknown), (unknown), Monika Heinzel‐Gutenbrunner, (unknown), Wilfried Roth, Anthony D. Ho, Peter Schirmacher, Michael Schmitt, Peter Dreger, Leopold Sellner	4
15	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR 2018 ·Cancer ·Anna Sureda, Mei‐Jie Zhang, Peter Dreger, Jeanette Carreras, Timothy S. Fenske, Hervé Finel, Harry C. Schouten, Silvia Montoto, Stephen Robinson, Sonali M. Smith, (unknown), Mehdi Hamadani, Marcelo C. Pasquini	40
16	Rituximab Purging and/or Maintenance in Patients Undergoing Autologous Transplantation for Relapsed Follicular Lymphoma: A Prospective Randomized Trial From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation 2013 ·Journal of Clinical Oncology ·Ruth Pettengell, Norbert Schmitz, Christian Gisselbrecht, Graeme Smith, W. N. Patton, Bernd Metzner, Dolores Caballero, Hervé Tilly, Jan Walewski, Isabelle Bence‐Bruckler, Bik To, Christian H. Geisler, Rik Schots, Eva Kimby, Christian Taverna, Tomáš Kozák, Peter Dreger, Ruzena Uddin, Carmen Ruiz de Elvira, Anthony H. Goldstone	77
17	High CD52 mRNA Expression Is An Adverse Prognostic Factor In Fludarabine-Refractory CLL Treated With Alemtuzumab On The Gcllsg CLL2H Trial 2013 ·Blood ·Johannes Bloehdorn, Martin Sill, Christian Langer, Axel Benner, (unknown), Thorsten Zenz, Andreas Bühler, Raymonde Busch, Peter Dreger, Ulrich Jäger, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer	1
18	Serum cytokeratin-18 fragments as quantitative markers of epithelial apoptosis in liver and intestinal graft-versus-host disease 2007 ·Blood ·Thomas Luft, Michael Conzelmann, Axel Benner, Michael A. Rieger, Michael Heß, (unknown), Martin Görner, Ute Hegenbart, Anthony D. Ho, Peter Dreger	79
19	Efficacy of subcutaneous Alemtuzumab (Campath-1H) in genetic high-risk, fludarabine-refractory CLL: CLL2H study of the German CLL Study Group (GCLLSG) 2005 ·mediaTUM (Technical University of Munich) ·S. Stilgenbauer, Alexander Kröber, Dirk Winkler, Dirk Kienle, Robert Busch, Michael Hallek, M. Hensel, Eva Lengfelder, Lorenz Trümper, Peter Dreger, Ulrich Jäger, H. Döhner	18
20	Allogeneic Peripheral Blood Progenitor Cells: Current Status and Future Directions 1996 ·Journal of Hematotherapy ·Peter Dreger, (unknown), Lutz Uharek, N Schmitz	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact